Omeprazole 20/40 mg — Membership Pricing
Omeprazole 20/40 mg is not confirmed for no-additional-cost pricing. Membership pricing may be available; confirm the price with the dispensing pharmacy.
Omeprazole 20/40 mg Pricing
| Pricing type | Price |
|---|---|
| TheDrugClub | Membership pricing may be available |
| Typical Retail | $110.00 |
Membership pricing may be available; confirm the price with the dispensing pharmacy.
About Omeprazole 20/40 mg
Omeprazole 20/40 mg is a prescription medication. Ask your doctor if Omeprazole 20/40 mg is right for you.
Other strengths and forms of Omeprazole
Conditions Treated with Omeprazole 20/40 mg
How to Check Omeprazole 20/40 mg Pricing
- Join TheDrugClub for $19.95/month
- Receive your member card by email
- Present your card at a participating pharmacy
- Check active-formulary eligibility or available membership pricing
Omeprazole 20/40 mg at Participating Pharmacies
- CVS Pharmacy
- Walgreens
- Walmart Pharmacy
- Rite Aid
- Kroger Pharmacy
- Costco Pharmacy
- Albertsons
- Safeway
- Publix Pharmacy
- H-E-B Pharmacy
Pharmacy participation and fulfillment options vary. Present your membership card and confirm current pricing before filling.
Related medications
Other medications associated with the same conditions in this catalog.
Also listed for Peptic Ulcer Disease / H. pylori
About Omeprazole 20/40 mg
Omeprazole 20 mg and 40 mg are widely prescribed medications renowned for their effectiveness in managing acid-related conditions. As a cornerstone for many seeking relief, understanding its benefits and accessibility is key.
The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.
What Omeprazole 20/40 mg is approved for (FDA label)
Omeprazole is a proton pump inhibitor (PPI) indicated for the: • Treatment of active duodenal ulcer in adults (1.1) • Eradication of Helicobacter pylori to reduce the risk of duodenal ulcer recurrence in adults (1.2) • Treatment of active benign gastric ulcer in adults (1.3) • Treatment of symptomatic gastroesophageal reflux disease (GERD) in patients 2 years of age and older (1.4) • Maintenance of healing of EE due to acid-mediated GERD in patients 2 years of age and older (1.6) • Pathologic hypersecretory conditions in adults (1.7) 1.1 Treatment of Active Duodenal Ulcer Omeprazole delayed-release capsules are indicated for short-term treatment of active duodenal ulcer in adults. Most patients heal within four weeks.
Source: Read the full FDA label on DailyMed. Label effective date: August 28, 2026.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Dosage forms and strengths for Omeprazole 20/40 mg (FDA label)
Omeprazole delayed-release capsules USP, 20 mg are off-white to pale yellow, spherical, enteric coated pellets filled in size '2' hard gelatin capsule shells with opaque purple colored cap and opaque grey colored body, imprinted 'OMEPRAZOLE' 20 mg on cap and 'R644' on body with black ink. Omeprazole delayed-release capsules, 20 mg (3)
Source: FDA prescribing information (DailyMed). Set ID: 63b3982a-b541-4b0d-99d4-93a673e57d46. SPL document ID: 5a1de2b5-8ef3-f37b-e063-6394a90ae77e. Label effective date: August 28, 2026. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Adverse reactions for Omeprazole 20/40 mg (FDA label)
The following serious adverse reactions are described below and elsewhere in labeling: • Acute Tubulointerstitial Nephritis [see Warnings and Precautions (5.2) ] • Clostridium difficile -Associated Diarrhea [see Warnings and Precautions (5.3) ] • Bone Fracture [see Warnings and Precautions (5.4) ] • Cutaneous and Systemic Lupus Erythematosus [see Warnings and Precautions (5.6) ] • Cyanocobalamin (Vitamin B-12) Deficiency [see Warnings and Precautions (5.8) ] • Hypomagnesemia and Mineral Metabolism [see Warnings and Precautions (5.9) ] • Fundic Gland Polyps [seeWarnings and Precautions (5.13) ] Adults: Most common adverse reactions in adults (incidence ≥2%) are • Headache, abdominal pain, nausea, diarrhea, vomiting, and flatulence (6) Pediatric patients (2 to 16 years of age): • Safety profile similar to that in adults, except that respiratory system events and fever were the most frequently reported reactions in pediatric studies. (8.4) To report SUSPECTED ADVERSE REACTIONS, contact Dr.
Source: FDA prescribing information (DailyMed). Set ID: 63b3982a-b541-4b0d-99d4-93a673e57d46. SPL document ID: 5a1de2b5-8ef3-f37b-e063-6394a90ae77e. Label effective date: August 28, 2026. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Contraindications for Omeprazole 20/40 mg (FDA label)
• Omeprazole delayed-release capsules are contraindicated in patients with known hypersensitivity reactions including anaphylaxis to the formulation or any substituted benzimidazole. Hypersensitivity reactions may include anaphylaxis, anaphylactic shock, angioedema, bronchospasm, acute tubulointerstitial nephritis, and urticaria [see Warnings and Precautions ( 5.2 ), Adverse Reactions (6) ]. • Proton pump inhibitors (PPIs), including omeprazole, are contraindicated in patients receiving rilpivirine-containing products [see Drug Interactions (7) ]. • For information about contraindications of antibacterial agents (clarithromycin and amoxicillin) indicated in combination with omeprazole, refer to the CONTRAINDICATIONS section of their package inserts. • Patients with known hypersensitivity to substituted benzimidazoles or any component of the formulation. (4) • Patients receiving rilpivirine-containing products. ( 4 , 7 ) • Refer to the Contraindications section of the prescribing information for clarithromycin and amoxicillin, when administered in combination with omeprazole. (4)
Source: FDA prescribing information (DailyMed). Set ID: 63b3982a-b541-4b0d-99d4-93a673e57d46. SPL document ID: 5a1de2b5-8ef3-f37b-e063-6394a90ae77e. Label effective date: August 28, 2026. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Warnings and precautions for Omeprazole 20/40 mg (FDA label)
Gastric Malignancy: In adults, symptomatic response does not preclude the presence of gastric malignancy.
Source: FDA prescribing information (DailyMed). Set ID: 63b3982a-b541-4b0d-99d4-93a673e57d46. SPL document ID: 5a1de2b5-8ef3-f37b-e063-6394a90ae77e. Label effective date: August 28, 2026. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Drug interactions for Omeprazole 20/40 mg (FDA label)
Tables 3 and 4 include drugs with clinically important drug interactions and interaction with diagnostics when administered concomitantly with omeprazole and instructions for preventing or managing them. Consult the labeling of concomitantly used drugs to obtain further information about interactions with PPIs. Table 3: Clinically Relevant Interactions Affecting Drugs Co-Administered with Omeprazole and Interaction with Diagnostics Antiretrovirals Clinical Impact: The effect of PPIs on antiretroviral drugs is variable. The clinical importance and the mechanisms behind these interactions are not always known.
Source: FDA prescribing information (DailyMed). Set ID: 63b3982a-b541-4b0d-99d4-93a673e57d46. SPL document ID: 5a1de2b5-8ef3-f37b-e063-6394a90ae77e. Label effective date: August 28, 2026. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.